Abiopharma

Cybin Announces Senior Leadership Changes

BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism

Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025

Royalty Pharma and Zenas Biopharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

New Form 8-K - PRECISION BIOSCIENCES INC Filed: 2025-09-02 AccNo: 0001357874-25-000005 Size: 142 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

New Form 6-K - DR REDDYS LABORATORIES LTD Filed: 2025-09-02 AccNo: 0001135951-25-000006 Size: 150 KB

UTHR: Notification

Moderna - Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism

New Form 8-K - IONIS PHARMACEUTICALS INC Filed: 2025-09-02 AccNo: 0001140361-25-033541 Size: 214 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Olema Pharmaceuticals, Inc. Filed: 2025-09-02 AccNo: 0001750284-25-000007 Size: 600 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Editas Medicine, Inc. Filed: 2025-09-02 AccNo: 0001650664-25-000134 Size: 207 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

UTHR: United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis

New Form 6-K - KAMADA LTD Filed: 2025-09-02 AccNo: 0001213900-25-082903 Size: 20 KB

More Than 450 Companies Drive Speed to Market with Veeva RIM